Product Warnings Updated For Glp-1 Ra Class
Summary The Australian Therapeutic Goods Administration has updated safety warnings for GLP-1 and dual GIP/GLP-1 receptor agonist medicines, which are used to treat type 2 diabetes and obesity, due to two identified safety issues. This affects products distributed across Australia. The warnings have been updated to reflect new safety information about this class of medications.
- Reason
- We have updated the product warnings for GLP-1 and dual GIP/GLP-1 receptor agonists for two separate safety issues. This relatively new and high-profile class of medicines is used to treat type 2 diabetes mellitus and/or obesity.
- Classification
- Class II
- Category
- drug recall
- Country
- Australia
- Agency
- Therapeutic Goods Administration
- Recall date
- 2025-12-01
- Status
- Ongoing
- Distribution
- Australia-wide
Official recall notice from Therapeutic Goods Administration
Recall details on Nibble Recalls: https://trynibble.app/recalls/52ca2d96-8caa-403d-8193-160763382656